Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
Condition(s):Multiple Sclerosis, Relapsing-Remitting; Multiple SclerosisLast Updated:June 27, 2019Completed
Hide Studies Not Open or Pending
Condition(s):Multiple Sclerosis, Relapsing-Remitting; Multiple SclerosisLast Updated:June 27, 2019Completed
Condition(s):Plaque PsoriasisLast Updated:August 9, 2016Withdrawn
Condition(s):Multiple Sclerosis, Secondary ProgressiveLast Updated:April 26, 2017Terminated
Condition(s):Multiple Sclerosis, Relapsing-RemittingLast Updated:October 23, 2017Completed
Condition(s):Plaque PsoriasisLast Updated:May 27, 2022Completed
Condition(s):Relapsing-Remitting Multiple Sclerosis; Multiple SclerosisLast Updated:November 20, 2018Completed
Condition(s):RRMSLast Updated:July 28, 2021Completed
Condition(s):Relapsing Forms of Multiple SclerosisLast Updated:March 21, 2017Completed
Condition(s):Relapsing-Remitting Multiple SclerosisLast Updated:June 7, 2016Completed
Condition(s):Multiple Sclerosis, Relapsing-RemittingLast Updated:June 15, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.